Right here in Australia, we have several clinical trials aiming to treat the root cause of HD, which is the production of the abnormal HD protein.  

On this page we provide information and links to three of the most promising trials (2 from Wave, and 1 from Roche). In addition to the trials that are running here in Australia, additional trials are underway for HD in other locations across the world.  Not all trials are currently available in Australia. 

If you want additional information about trials, you may wish to contact staff at your nearest HD clinic.

Wave Clinical Trials

Wave Life Sciences are conducting two Phase 1b/2a clinical trials called PRECISION-HD1 and PRECISION-HD2. A third trial PRECISION-HD3, will be underway soon in Australia.

These trials aim to specifically target and reduce the amount of mutant huntingtin protein produced, whilst leaving the healthy huntingtin protein untouched.

The treatment for the Wave trials is administered into the spinal canal via a lumbar puncture. The main goal of these trials is to examine the safety and tolerability of each drug. Researchers are also interested to understand how each drug affects the levels of huntingtin protein produced, and their effectiveness against the clinical symptoms of HD. A full examination of the treatment effects will only be possible in the next stage of study, a Phase III trial, which has more participants so that it can examine the full benefits and side effects for patients. 

Both trials involve the same procedures, however participants in PRECISION-HD1 will be administered a drug called WVE-120101, whilst those participating in PRECISION-HD2 will receive the drug WVE-120102.

There are currently five clinical trial sites in Australia investigating this drug.  These sites are located in Melbourne, Sydney, Brisbane and Perth.

Roche Clinical Trials

Sponsored by Roche, the GENERATION HD1 study administers eligible HD patients with a drug that has been shown to reduce the production of the huntingtin protein. This protein is responsible for HD symptoms.

The purpose of this phase III trial is to study whether treatment with this drug slows the progression of symptoms.

This study also aims to:

1) better understand whether any benefits observed during the trial are due to the drug, and not to other factors, and

2) determine how often the drug should be administered to provide any observed patient benefits.

All participants are to attend study visits every 2 months for either drug or placebo injection via a lumbar puncture. Participants will be randomised to one of three group in which they’ll receive either:

1) study drug once every 2 months,

2) study drug once every 4 months, or

3) study drug once every 4 months and placebo every 2 months.

The Roche trial has already enrolled more than 660 people with HD across 80-90 clinics in 15 countries around the world, including Australia. Enrolment for this trial is now closed so no new participants are being added. In Australia we have three sites involved in the trial, which are located in Melbourne and Sydney. 

Links:

Optional – if this page provides resources list them here

For more information about Wave Life Sciences, you can access their website here.

For more information about Roche, you can access their website here.

Huntington’s Disease Network of Australia

Contact Us

  • +61 3 9902 0081
  • info@hdna.com.au
  • ABN: 039 393 9290 2292
  • © 2021 HDNA. All Rights Reserved.